We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GL:NYSEGlobe Life Inc. Analysis

Data as of 2026-09-27 - not real-time

$167.04

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

At $167.04, Globe Life Inc. shows no decisive moving-average alignment, leaving the trend neutral. It has lost 7.5% over the past 30 days. RSI sits at 34.9, which reads as approaching oversold, and MACD momentum is bearish. Watch $166.05 as support and $177.00 as the nearer resistance level.
On valuation the read is undervalued — earnings multiple of 11.1 versus a 15.6 sector average, below the peer group. The average analyst target implies 16.1% above today's level. Revenue is growing at 8.0% on a 19.6% profit margin. The 0.79% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 18.3%, a beta of 0.29 and a maximum drawdown of 10.2%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 6/10 long-term conviction.

Top Market Events

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in...Die Globe-Life-Aktie notierte am 21.09.2026 bei 139,19 USD an der NYSE. Die Marktkapitalisierung lagDie Globe-Life-Aktie schloss am 18.09.2026 an der NYSE bei 173,42 USD und liegt damit nahe dem Analy

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Trading above the 200-day average of 156.68
  • MACD momentum is negative
  • 30-day price change of -7.5%

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 11.1 versus sector average of 15.6
  • Trading above the 200-day average of 156.68
  • Analyst targets imply +16.1% versus the current price

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 11.1 versus sector average of 15.6
  • Analyst targets imply +16.1% versus the current price
  • Profit margin of 19.6% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth8.00%
Profit Margin19.58%
P/E Ratio11.1
ROE20.94%
ROA3.36%
Debt/Equity55.67
P/B Ratio2.1
Op. Cash Flow$1.4B
Free Cash Flow$1.2B
Industry P/E15.6

Technical Analysis

TrendNeutral
RSI34.9
Support$166.05
Resistance$177.00
MA 20$171.70
MA 50$176.14
MA 200$156.68
MACDBearish
VolumeIncreasing
Fear & Greed Index94.88

Valuation

Fair Value$215.50
Target Price$193.91
Upside/Downside16.09%
GradeUndervalued
TypeBlend
Dividend Yield0.79%

Risk Assessment

Beta0.29
Volatility18.28%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.